CRISPR-Cas Systems Based Molecular Diagnostic Tool for Infectious Diseases and Emerging 2019 Novel Coronavirus (COVID-19) Pneumonia.

CRISPR-Cas Systems Based Molecular Diagnostic Tool for Infectious Diseases and Emerging 2019 Novel Coronavirus (COVID-19) Pneumonia.

Publication date: May 13, 2020

Emerging infectious diseases, the persistent potential for destabilizing pandemics, remain a global threat leading to excessive morbidity and mortality. The current outbreak of pneumonia caused by 2019 novel coronavirus (COVID-19) illustrated difficulties in lack of effective drugs for treatment. Accurate and rapid diagnostic tools are essential for early recognition and treatment of infectious diseases, allowing timely implementation of infection control, improved clinical care and other public health measures to stop the spread of the disease. CRISPR-Cas technology speed up the development of infectious disease diagnostics with high rapid and accurate. In this review, we summarize current advance regarding diverse CRISPR-Cas systems, including CRISPR-Cas9, CRISPR-Cas12 and CRISPR-Cas13, in the development of fast, accurate and portable diagnostic tests and highlight the potential of CRISPR-Cas13 in COVID-19 Pneumonia and other emerging infectious diseases diagnosis.

Concepts Keywords
Cas9 CRISPR
Coronavirus Biotechnology
CRISPR Immune system
Infection Control Genetic engineering
Infectious Diseases Enzymes
Morbidity Genome editing
Mortality Life sciences
Pandemics Branches of biology
Pneumonia Timely infection
Cas9
Human Nature
Cas1
Diagnostic tests

Semantics

Type Source Name
disease MESH Infectious Diseases
disease MESH Pneumonia
disease MESH Emerging infectious diseases
disease MESH infection
disease MESH development
disease MESH diagnosis

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *